FDA’s Oncologic Drugs Advisory Committee (ODAC) critiques a major lymphoma trial for having too few U.S. participants, warning …
FDA’s Oncologic Drugs Advisory Committee (ODAC) critiques a major lymphoma trial for having too few U.S. participants, warning …
Combination therapy delivers promising efficacy and manageable safety in PD-1 refractory head and neck squamous cell carcinoma
Oral brain-penetrant NLRP3 inhibitor and new collaborations place BioAge at center of metabolic aging drug development
Trial halt and valuation collapse trigger major workforce reduction at fibrosis-focused biotech
Dual clinical studies reveal statistically meaningful benefits for patients with MSA, highlighting a leap forward for disease-modifying treatment …
New research unveiled at the American Association for Cancer Research meeting points to promising treatments for head and …
Zydus’ experimental therapy demonstrates significant improvements in liver function and patient outcomes, signaling new hope in a disease …
New safety and efficacy evidence supports expanded use of mavacamten in oHCM patients
On 15 April 2025, the European Medicines Regulatory Network rolled out an interactive trial map—empowering patients and professionals …
Targeted treatment approach shows potential to reshape how antidepressants are prescribed
Already a subscriber? Log in